留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

治疗痛风药物研究进展

徐娜,  陈海生

downloadPDF
文章导航 > 药学实践与服务  > 2013 >  31(1): 14-18
徐娜, 陈海生. 治疗痛风药物研究进展[J]. 药学实践与服务, 2013, 31(1): 14-18. doi: 10.3969/j.issn.1006-0111.2013.01.004
引用本文: 徐娜, 陈海生. 治疗痛风药物研究进展[J]. 药学实践与服务, 2013, 31(1): 14-18. doi: 10.3969/j.issn.1006-0111.2013.01.004
shu
XU Na, CHEN Hai-sheng. Advance in drug therapy of gout[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(1): 14-18. doi: 10.3969/j.issn.1006-0111.2013.01.004
Citation: XU Na, CHEN Hai-sheng. Advance in drug therapy of gout[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(1): 14-18. doi: 10.3969/j.issn.1006-0111.2013.01.004
shu

治疗痛风药物研究进展

doi: 10.3969/j.issn.1006-0111.2013.01.004

  • 第二军医大学药学院天然药物化学教研室, 上海 200433

基金项目: 上海市中药现代化专项资助(09dZ1974000);上海市重点学科建设项目(B906).

Advance in drug therapy of gout

  • Department of Phytochemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 摘要: 随着人们生活水平的提高, 痛风的发病率不断上升并出现低龄化, 寻找高效低毒的抗痛风药物成为当务之急。目前,对于痛风的常规治疗仍以西药为主,这些药物以不同的作用机制达到缓解或治疗痛风的目的,但临床发现它们都具有一定的毒副作用。近年来,越来越多的研究者着手于抗痛风天然药物的开发,其疗效与毒副作用尚待进一步的临床验证。本文对目前临床上常用的抗痛风药物及正在研发中的抗痛风药物进行了综述,总结痛风病不同分期的药物治疗特点,阐述各期药物治疗潜在危害和处理方法,归纳抗高尿酸血症或痛风的中药研究,为开发新型抗痛风药物提供有效途径,并对抗痛风新药的研发进行了展望。
    Abstract: With the development of the living standard, the incidence of gout was rising and the trend of patient age with gout getting younger. Developing high-effective and low-adverse anti-gout drugs was a priority of the research agenda. At present, conventional therapies of gout lean on western medicines. These drugs relieved or treated gout with different mechanisms, but all of them had different side-effects. Recently, more and more researchers started to develop traditional Chinese medicine to treat gout and their effectiveness and the side-effects need further clinical verification. The commonly used anti-gout drugs or new drugs under research including their treatment characteristics, potential hazards and their therapeutic principles at different clinical stages were summarized in this article, especially in some anti-hyperuricemia or anti-gout Chinese Medicine, which gave an effective way to develop new anti-gout drugs.
  • [1] Hayden MR, Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type diabetes mellitus: the urate redox shuttle[J]. Nutr Metab(Lond), 2004, 1 (1):10.
    [2] Miao Z, Li CG, Chen Y, et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of eastern China[J]. J Rheumatol, 2008, 35 (9):1859.
    [3] 江 瀛,徐领城. 痛风的药物治疗进展[J]. 海峡药学, 2010, 22 (1):100.
    [4] Howard SS, Donna BY, Joshua MS. Gout: Current Insights and Future Perspectives[J]. Journal of Pain, 2011, 12 (11):1113.
    [5] Emmerson BT. The management of gout[J]. Clinical Biochemistry, 1997, 30 (3):253.
    [6] Miguelez R, Palacios L, Navarru F, et al. Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antipreteinase activity in an experimental model of acute urate crystal arthritis[J]. Lipid Mediat Cell Sisn, 1996, 13 (1):35.
    [7] Tausche AK, Richter K, Giassler A, et al. Severe gouty arthriti refractory to anti-inflammatory drugs:treatment with anti-tumouneerosis actor alpha as a new therapeutic option[J]. Ann Rheum Dis, 2004, 63 (10):1351.
    [8] Schumacher HR, Sundy JS, Terke LR, et al. Placebo controlled study of rilonacept for gout flare prophylaxis during initiation of urate lowering therapy[J]. Arthritis Rheum, 2009, 60 (4): 410
    [9] So A, Meulemeester MD, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-reat gouty arthritis: Results of a multicenter, phase II, dose-ranging study[J]. Arthritis Rheum, 2010, 62(10): 3064.
    [10] Singh D, Huston KK. IL-1 inhibition with anakinra in a patient with refractory gout[J]. J Clin Rheumatol, 2009, 15(7):366.
    [11] 朱深银,周远大,杜冠华.防治痛风药物的研究进展[J].医药导报,2006,25(8):803.
    [12] Takano Y, Haze-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, anovel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase[J]. Life sci, 2005, 76: 1835.
    [13] Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease[J]. New Drug Class, 2011, 377:165.
    [14] Mohamed DA, Al-Okbi SY. Evaluation of anti-gout activity of some plant food extracts[J]. Polish Journal Of Food and Nut, 2008, 58 (3):389.
    [15] Tian YQ, Kou JP, Li LZ, et al. Anti-inflammatory effect of aqueous extract from Radix Liriope muscari and its major active fraction and component[J]. Chinese Journal of Natural Medicines, 2011, 9 (3):0222.
    [16] 姚 佳,曹晓燕,王结之. 6种秦艽镇痛和抗炎活性的比较[J].现代生物医学进展, 2010, 10(24):4642.
    [17] 廉 莲,贾 天.黄柏及其炮制品的抗痛风作用研究[J].安徽农业科学, 2011,39(15): 8911.
    [18] Kong LD, Yang C, Ge F. et al. A Chinese herbal medicine Ermiao wall reduces serum uric acid level and inhibits liver xanthine dehydmgene and xanthine oxidase in mice[J]. J Ethnopharmaco1, 2004, 93 (23):325.
    [19] Powanda MC, Rainsford KD. A toxicological investigation of a celery seed extract having anti-inflammatory activity[J]. Inflammopharmacology, 2010, 19 (4):227.
    [20] 仝国辉,张 懿,张瑶楠. 芹菜籽提取物对高尿酸血症大鼠的影响[J]. 食品科学, 2008, 29 (6):641.
    [21] Ahamd NS, Farmn M, Najmi MH, et al. Pharmacological basis for use of Pistacia integerrima leaves in hyperuricemia and gout[J]. J Ethnopharmacol, 2008,117 (3):478.
    [22] Umamaheswari M, Asokkuar K, Sivashanmugam AT, et al. In vitro xanthine oxidase inhibitory activity of the fractions of Erythrina stricta roxb[J]. J Ethnopharmacol, 2009, 124(3): 646.
    [23] Murugaiyah V, Chan KL. Mechanisms of antihyperuricemic effect of Phyllanthus niruri and its lignan constituents[J]. J Ethnopharmacol, 2009, 124 (2):233.
    [24] Chien SC, Yang CW, Tseng YH, et al. Lonicera hypoglauca inhibits xanthine oxidase and reduces serum uric acid in mice[J]. Planta Med, 2009,75 (4):302.
    [25] Maitraie D, Hung CF, Tu HY, et al. Synthesis, anti-inflammatory and antioxidant activities of 18B-glycyrrhetinic acid derivatives as chemical mediators and xanthine oxidase inhibitors[J]. Bioorg Med Chem,2009,17 (7):2785.
    [26] Wang Y, Zhu JX, Kong LD, et al. Administration of procyanidins from grape seecls reduces serum uric acid levels and decreases hepatic xanthine dehydrogenase/oxidase activities in oxonate-treated mice[J]. Basic Clin Pharmacology & Toxicology, 2004, 94 (5):232.
    [27] Zhu JX, WangY, Kong LD, et al. Effects of Biota orientalis extract and its flavonoid constituents quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver[J].J Ethnopharmacol, 2004, 93 (1): 133.
    [28] Yoshizumi K, Nishioka N, Tsuji T. Xanthine oxidase inhibitory activity and hyypouricemia effect of propolis in rats[J]. Journal of the Pharmaceutical Society of Japan, 2005, 125 (3):315.
    [29] Lin HC, Tsai SH, Chen CS, et al. Structure-activity relationship of coumarin derivatives on xanthine oxidase-inhibiting and free radical-scavenging activities[J]. Biochem Pharmacol,2008, 75: 1416.
    [30] Odontuya GJ, Hoult RS, Houghton PJ. Structure-activity relationship for antiinflammatory effect of luteolin and its derived glycosides[J]. Phytother Res, 2005, 19, 782.
    [31] 薛 莎,朱琼洁,马 威. 伸秦组方对高尿酸血症小鼠的影响[J].中国药物经济学,2010, 2:87.
    [32] 杨和金,苏 梅,赵春梅,等. 痛风液抗痛风性关节炎的实验研究[J].中草药, 2010, 9 (41):1504.
    [33] 陈海生,乔丽名,刘建国,等. 芹菜籽黄酮类和香豆素类化合物在制备防治痛风药物的用途,中国发明专利 ZL 200710062800.6.
  • [1] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
    [2] 孙丹倪, 黄勇, 张嘉宝, 王培.  代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
    [3] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [4] 王晓飞, 张颖, 顾佳钰, 胡馨儿, 张海, 曹岩.  表面等离子共振传感器的识别元件在医药领域中的研究应用进展 . 药学实践与服务, 2024, 42(): 1-9. doi: 10.12206/j.issn.2097-2024.202309014
    [5] 钱淑雨, 李铁军.  耐碳青霉烯类肠杆菌耐药机制的研究进展 . 药学实践与服务, 2024, 42(10): 419-425. doi: 10.12206/j.issn.2097-2024.202405005
    [6] 刘汝雄, 杨万镇, 涂杰, 盛春泉.  铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075
    [7] 顾佳钰, 胡馨儿, 王晓飞, 张颖, 张海, 曹岩.  侧流免疫层析定量检测方法的研究进展 . 药学实践与服务, 2024, 42(7): 273-277, 284. doi: 10.12206/j.issn.2097-2024.202307037
    [8] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
    [9] 徐飞, 陈瑾, 鲁育含, 李志勇.  肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
    [10] 陈莹, 许子华, 胡北, 崔亚玲, 高欢, 吴琼.  通便灵胶囊治疗便秘的药效与机制研究 . 药学实践与服务, 2024, 42(): 1-7. doi: 10.12206/j.issn.2097-2024.202404008
    [11] 崔亚玲, 吴琼, 马良煜, 胡北, 姚东, 许子华.  肝素钠肌醇烟酸酯乳膏中肌醇烟酸酯皮肤药动学研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404006
    [12] 杨凤艳, 张月, 陈恩贤, 缪雪蓉, 魏凯.  瑞马唑仑临床应用研究进展 . 药学实践与服务, 2024, 42(9): 365-374. doi: 10.12206/j.issn.2097-2024.202405026
    [13] 张林晨, 张小琴, 张俊平.  山楂酸药理作用的研究进展 . 药学实践与服务, 2024, 42(5): 185-189. doi: 10.12206/j.issn.2097-2024.202307052
    [14] 郭灵怡, 刘艳超, 高路, 刘瑞瑶, 吕权真, 俞媛.  醋酸卡泊芬净单硬脂酸甘油酯纳米粒抗白色念珠菌感染的增效作用研究 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202310043
    [15] 陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠.  UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(8): 341-345. doi: 10.12206/j.issn.2097-2024.202404082
    [16] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [17] 夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞.  核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(9): 399-401, 406. doi: 10.12206/j.issn.2097-2024.202404063
    [18] 马兹芬, 许维恒, 金煜翔, 薛磊.  食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
    [19] 宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦.  脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 1-5. doi: 10.12206/j.issn.2097-2024.202405059
    [20] 赖立勇, 夏天爽, 徐圣焱, 蒋益萍, 岳小强, 辛海量.  中药青蒿抗氧化活性的谱效关系研究 . 药学实践与服务, 2024, 42(5): 203-210, 216. doi: 10.12206/j.issn.2097-2024.202211012
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  4148
  • HTML全文浏览量:  383
  • PDF下载量:  729
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-02-09
  • 修回日期:  2012-05-21

治疗痛风药物研究进展

doi: 10.3969/j.issn.1006-0111.2013.01.004
  • 第二军医大学药学院天然药物化学教研室, 上海 200433
    • 基金项目:  上海市中药现代化专项资助(09dZ1974000);上海市重点学科建设项目(B906).
  • 收稿日期: 2012-02-09
  • 修回日期: 2012-05-21

摘要: 随着人们生活水平的提高, 痛风的发病率不断上升并出现低龄化, 寻找高效低毒的抗痛风药物成为当务之急。目前,对于痛风的常规治疗仍以西药为主,这些药物以不同的作用机制达到缓解或治疗痛风的目的,但临床发现它们都具有一定的毒副作用。近年来,越来越多的研究者着手于抗痛风天然药物的开发,其疗效与毒副作用尚待进一步的临床验证。本文对目前临床上常用的抗痛风药物及正在研发中的抗痛风药物进行了综述,总结痛风病不同分期的药物治疗特点,阐述各期药物治疗潜在危害和处理方法,归纳抗高尿酸血症或痛风的中药研究,为开发新型抗痛风药物提供有效途径,并对抗痛风新药的研发进行了展望。

English Abstract

徐娜, 陈海生. 治疗痛风药物研究进展[J]. 药学实践与服务, 2013, 31(1): 14-18. doi: 10.3969/j.issn.1006-0111.2013.01.004
引用本文: 徐娜, 陈海生. 治疗痛风药物研究进展[J]. 药学实践与服务, 2013, 31(1): 14-18. doi: 10.3969/j.issn.1006-0111.2013.01.004
shu
XU Na, CHEN Hai-sheng. Advance in drug therapy of gout[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(1): 14-18. doi: 10.3969/j.issn.1006-0111.2013.01.004
Citation: XU Na, CHEN Hai-sheng. Advance in drug therapy of gout[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(1): 14-18. doi: 10.3969/j.issn.1006-0111.2013.01.004
shu

    全文HTML

参考文献 (33)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计